Article

A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells

Department of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea.
Cancer Research (Impact Factor: 9.28). 09/2007; 67(15):7327-34. DOI: 10.1158/0008-5472.CAN-06-4766
Source: PubMed

ABSTRACT Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptotic cell death in a variety of tumor cells without significant cytotoxicity on normal cells. However, many cancer cells with apoptotic defects are resistant to treatment with TRAIL alone, limiting its potential as an anticancer therapeutic. Here, we report on the tumoricidal activity of a human single-chain fragment variable, HW1, which specifically binds to TRAIL receptor 2 (TR2) without competing with TRAIL for the binding. HW1 treatment as a single agent induces autophagic cell death in a variety of both TRAIL-sensitive and TRAIL-resistant cancer cells, but exhibits much less cytotoxicity on normal cells. The HW1-induced autophagic cell death was inhibited by an autophagy inhibitor, 3-methyladenine, or by RNA interference knockdown of Beclin-1 and Atg7. We also show that the HW1-mediated autophagic cell death occurs predominantly via the c-Jun NH(2)-terminal kinase pathway in a caspase-independent manner. Analysis of the death-inducing signaling complex induced by HW1 binding to TR2 exhibits the recruitment of TNF receptor-associated death domain and TNF receptor-associated factor 2, but not Fas-associated death domain, caspase-8, or receptor-interacting protein, which is distinct from that induced by TRAIL. Our results reveal a novel TR2-mediated signaling pathway triggering autophagic cell death and provides a new strategy for the elimination of cancer cells, including TRAIL-resistant tumors, through nonapoptotic cell death.

0 Followers
 · 
136 Views
  • Source
    • "Double labeling immunohistochemistry (Fig. 4E) with BrdU (green) and Iba1 (red) antibodies instead revealed that in the cortex newborn cells around amyloid plaques had differentiated into microglial cells. In the AD brain, oxidative stress and the inflammatory reaction work together in the pathogenic cascade leading to neurodegeneration [24]. Microglia and astrocytes activated by A␤ produce and secrete chemokines, various pro-inflammatory cytokines, reactive oxygen species and NO that may result in neuronal damage [20]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to investigate the microglia-driven apoptosis and the Aβ deposits triggered generation of new microglial cells in the neocortex of TgCRND8 mice. Three- and seven-month-old TgCRND8 mice, displaying an early and widespread amyloid deposition, respectively, were used. In 7-month-old TgCRND8 mice the Aβ-associated glial reaction was accompanied by an intense immunoreactivity of both TNF-α and inducible nitric oxide synthase, increased immunoreactivity of the pro-apoptotic protein Bax and a decrease in levels of the anti-apoptotic protein Bcl-2.Cortical and hippocampal neurons of TgCRND8 mice displayed higher immunoreactivity and higher nuclear expression of the transcription factor NF-kB than controls. It is possible that such an increase could represent a defence/compensatory response to degeneration. These findings indicate that Aβ deposits activate brain-resident microglia population and astrocytes, and induce overproduction of inflammatory mediators that enhance pro- and anti-apoptotic cascades. In both 3- and 7-month-old TgCRND8 mice apparent gliogenesis was present in the vicinity of Aβ plaques in the neocortex, indicating that microglia have a high proliferative rate which might play a more complex role than previously acknowledge.
    Neuroscience Letters 10/2011; 506(1):94-9. DOI:10.1016/j.neulet.2011.10.056 · 2.06 Impact Factor
  • Source
    • "Binding of His tag-fused KD548 to the target proteins was determined by ELISA (Park et al. 2007). ELISA plates (Nunc; Invitrogen Ltd., Carlsbad, CA, USA) were coated with serially diluted His tag-fused KD548, TRAIL, and PgnKD2 proteins (0.001–3 μM) overnight at 4°C and blocked with 1% (w/v) bovine serum albumin (BSA) for 1 h at 37°C. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human kringle domains (KDs) are ubiquitously expressed binding modulators that fold into seven flexible loops and it has been previously demonstrated that KDs can be engineered toward target-specific binding proteins as a non-antibody protein scaffold. Here, we report a method for efficient expression of a KD derivative (KD548)-a promising anti-cancer agent-by high-cell-density culture of Escherichia coli at a preparative scale production. The correct folding of KD548 requires three disulfide bonds. Nevertheless, cytoplasmic expression of KD548 in E. coli led to good yields of highly soluble proteins with high activity. For efficient expression, four sets of expression systems consisting of different promoters (lac or T7) and fusion tags (His or FLAG) were examined. Of these, the expression system using a combination of the T7 promoter with the FLAG tag resulted in the highest production in shake flask cultivation as well as in high-cell-density cultivation performed in a 6.6-L jar bioreactor. When protein expression was induced at high-cell density (optical density [OD] = 100) and when complex feeding solutions were supplemented, cell density (maximum OD = 184) and production yield (approximately 5.4 g/L) were significantly enhanced to values that were much higher than those found previously with Pichia cultivation (<8 mg/L).
    Applied Microbiology and Biotechnology 06/2011; 92(2):327-36. DOI:10.1007/s00253-011-3423-z · 3.81 Impact Factor
  • Source
    • "he multivalent hAY4 scFvs efficiently activated pro - apoptotic molecules , including caspase - 8 , in proportion to the incubation period , indicating that bivalency is required to activate the pro - apoptotic functions of DR4 . Although monovalent anti - DR5 scFv antibodies can directly activate DR5 and induce cell death ( Adams et al . , 2008 ; Park et al . , 2007 , 2009 ) , no monovalent anti - DR4 antibodies with cell death - inducing activity have been reported ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Development of agonistic monoclonal antibodies (mAbs) against the pro-apoptotic molecule death receptor 4 (DR4) [or tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) receptor 1] is an attractive anti-cancer strategy because of their potential for inducing tumor-specific cell death. In this study, we humanized an agonistic anti-DR4 AY4 scFv raised in mice (mAY4) by grafting the complementarity-determining regions (CDRs) onto a fixed human framework, while preserving the so-called Vernier zone residues, a group of framework (FR) residues directly underneath the CDRs, with the murine residues in the humanized antibody, hAY4. The humanized hAY4 scFv maintained the antigen binding affinity and epitope specificity of mAY4. To investigate how the valence of hAY4 scFv affects DR4-mediated cell death, bivalent and trivalent forms of hAY4 scFv were generated by linking a hinge region to the coiled-coil domain of a dimerizing leucine zipper and trimerizing isoleucine zipper, respectively. Compared to the monovalent and bivalent forms, the trivalent hAY4 scFv induced more potent caspase-dependent apoptotic cell death as evidenced by increased activation of caspase-8 and downstream pro-apoptotic molecules. Our results suggest that like other TNF family receptors, avidity-mediated oligomerization of DR4 augments the receptor-mediated apoptotic cell death by promoting intracellular cell death signaling.
    Molecular Immunology 10/2009; 47(4):816-24. DOI:10.1016/j.molimm.2009.09.041 · 3.00 Impact Factor
Show more

Preview

Download
3 Downloads
Available from